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Background: Various comorbidities influence the prognosis of patients with chronic
obstructive pulmonary disease (COPD). We investigated if liver fibrosis assessed using
fibrosis-4 index (FIB-4) is associated with all-cause mortality in patients with COPD.
Methods: We included 756 patients diagnosed with COPD between 2006 and 2010.
Medical records were retrospectively reviewed until 2018. FIB-4 was calculated using the
following equation: [age (years) × aspartate aminotransferase (IU/L)/(platelet count (109/L) ×
√alanine aminotransferase (IU/L))].
Results: From a total of 756 patients, 582 (76.9%) patients were categorized into survivor
and 174 (23.1%) into non-survivor groups. The non-survivor group was significantly older
with a higher proportion of male, smoker and lower FEV1/FVC ratio than the survivor group
(all P<0.05). Various comorbidities were more frequently observed in the non-survivor group
(P<0.05). In addition, the non-survivor group had significantly higher FIB-4 than the
survivor group (1.8 vs 1.4, P<0.001). In multivariate analysis, older age (hazard ratio [HR]
=1.05), underlying malignancy (HR=2.94), coronary artery occlusive disease (HR=1.58),
higher FIB-4 (HR=1.15), and higher GOLD stage (HR=1.26) were significantly associated
with the increased risk of all-cause mortality (P<0.05), whereas body mass index (HR=0.95)
was independently protective for all-cause mortality (all P<0.05). The high FIB-4 (>1.57)
group showed a significantly lower cumulative survival rate than the low FIB-4 (≤1.05)
group (P=0.031, Log-rank test). In multivariate regression analysis, higher FIB-4 indepen-
dently predicted the risk of acute exacerbation (odds ratio=1.08, P=0.034).
Conclusion: Higher fibrotic burden assessed using FIB-4 was independently predictive of
the increased risk of all-cause mortality and acute exacerbation in patients with COPD.
Keywords: chronic obstructive pulmonary disease, exacerbation, FIB-4, liver fibrosis,
mortality
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow
limitation and an increased inflammatory response of the airways.1 However,
beyond the airways, COPD is a complex and heterogeneous respiratory disease
involving multi-organ inflammation. Although the mechanisms are yet to be inves-
tigated in detail, chronic inflammation in COPD and comorbidities accelerate the
natural progression of one another.1 Therefore, systemic comorbidities of COPD are
important challenges in reducing future risks of mortality and exacerbation, which
are the main treatment goals in COPD.
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A recent study investigated the prevalence and severity
of non-alcoholic fatty liver disease (NAFLD), defined by
a noninvasive surrogate for the diagnosis of fatty liver, in
patients with COPD and showed a close association
between NAFLD and COPD.2 The prevalence of simple
steatosis, non-alcoholic steatohepatitis, and fibrotic liver
were 41%, 37%, and 61%, respectively, in patients with
COPD. Because NAFLD is primarily linked with meta-
bolic comorbidities of COPD and systemic inflammation,2
the authors insisted that NAFLD should be included
among COPD comorbidities, and hypothesized that
COPD progression in NAFLD might be attributable to
oxidative stress and systemic inflammation. Moreover,
several studies reported a significant association between
NAFLD and decreased lung function in the general
population.3–7 However, detailed underlying mechanisms
still remain unresolved.
Fibrosis-4 index (FIB-4), a noninvasive, simple-to-use
equation, which includes laboratory and clinical variables
such as aspartate aminotransferase (AST), alanine amino-
transferase (ALT), platelet count, and age as constituent
variables, was proposed to evaluate the degree of liver
fibrosis in patients with chronic liver diseases.8,9 FIB-4
has proven to be a significant prognostic predictor for the
development of hepatocellular carcinoma in patients with
chronic liver diseases.10–12 Besides evaluating chronic
liver diseases, FIB-4 has been used to assess liver fibrosis
and its relation with other systemic inflammatory diseases
or conditions, including arterial stiffness/abnormal central
hemodynamics in heart failure, cerebral white matter
hyperintensity, rheumatoid arthritis, and polyangiitis.13–17
Accordingly, we investigated whether liver fibrosis
assessed using FIB-4 is associated with all-cause mortality
in patients with COPD, based on the concept that liver




We extracted the details of 1,282 patients who were diag-
nosed COPD based on the 10th revision of the
International Statistical Classification of diseases and
Related Health Problems (ICD-10) codes and medications
prescribed from January 2006 to December 2010 in
Severance Hospital, South Korea.
The inclusion criteria were, (1) age ≥ 40 years; (2)
ICD-10 codes for COPD or emphysema (J43.0x-J44.x,
with the exception of J43.0 as primary or secondary
(within the fifth position) diagnosis); and (3) use of more
than one of the following COPD medications at least twice
per year, long-acting muscarinic antagonist, long-acting
beta-2 agonist (LABA), inhaled corticosteroid + LABA,
short-acting muscarinic antagonist (SAMA), short-acting
beta-2 agonist (SABA), SAMA + SABA, phosphodiester-
ase-4 inhibitor, systemic beta-agonist, or methylxanthine.
However, 84 patients without pulmonary function infor-
mation, 57 patients without obstructive pulmonary function,
312 patients with a history of asthma, and 73 patients with
chronic liver disease were excluded as they failed to fulfill
inclusion criteria (Figure 1). Finally, 756 patients with
COPD were enrolled and their medical records were retro-
spectively reviewed until 2018. Index date from when the
patients were followed up was defined as the date of the first
COPD medication prescribed to the patients.
The study protocol was consistent with the ethical
guidelines of the 1975 Declaration of Helsinki and was
approved by the Institutional Review Board (IRB) of
Severance University. The requirement for an informed
consent was waived on the acknowledgement of IRB of
Severance University, due to the reason that data given to
researchers are anonymized with no identifying informa-
tion available. Study data are available upon request, so
any interested researchers can access and share the data by
submitting a request and receiving the permission from the
corresponding author and IRB of Severance University.
The data will be provided anonymously.
Exacerbation
COPD exacerbation was defined as a ≥ 2-day aggravation
of one of the following three symptoms (cough, sputum,
and dyspnea) resulting in an unscheduled hospital visit,
a requirement of antibiotics and/or oral corticosteroids, or
hospitalization for additional treatment.
Assessment of Liver Fibrosis
FIB-4 was calculated using the following equation: age
(years) × aspartate aminotransferase (AST) (IU/L)/[plate-
let count (109/L) × √alanine aminotransferase (ALT) (IU/
L)]. The study population was divided into three risk
groups, low (Q1; (≤1.05)), intermediate (Q2-3), and high
(Q4; (>1.57)) FIB-4 groups.
Statistical Analysis
Categorical variables between the two groups were ana-
lyzed using the χ2 test and were expressed as number and
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percentage. Continuous variables between the two groups
were compared using Student’s t-test and were expressed
as mean ± standard deviation. The predictive role of FIB-4
for all-cause mortality was described as hazard ratio (HR)
using the multivariate Cox hazards model analysis and
Kaplan-Meier curve. The risk of exacerbation is described
as the odds ratio (OR) with 95% confidence interval (CI)
using generalized estimating equations for longitudinal
data of exacerbation. P-value of <0.05 was considered to
be statistically significant. All statistical analyses were




The baseline characteristics of the enrolled 756 patients
with COPD at the time of diagnosis are shown in Table 1.
The mean age was 67.9 years with a predominance of
male patients (85.1%). Among the underlying comorbid-
ities, hypertension was the most common (33.6%), fol-
lowed by malignancy (20.1%) and diabetes mellitus
(17.3%). Most patients with COPD were ever smokers
(82.5%). The initial pulmonary function test results
showed a mean FEV1 of 1.39 L (57% of predicted),
mean FVC of 2.48 L (69.9% of predicted), and mean
FEV1/FVC ratio of 56.1%. The mean FIB-4 was 1.53.
Comparison Between Survivors and
Non-Survivors
During the study period (mean follow-up, 6.1 years), 174
(23.1%) patients died, whereas 582 (76.9%) were alive.
When the baseline characteristics were compared (Table
2), non-survivors were significantly older (mean 71.3
years vs 66.9 years, P<0.001) and had a higher proportion
of males (91.4% vs 83.2%, P=0.007) and those with smok-
ing history (89.7% vs 80.3%, P=0.004) than survivors.
Various comorbidities including malignancy, cerebral vas-
cular disease, coronary artery occlusive disease (CAOD),
congestive heart failure, chronic kidney disease, diabetes
mellitus, and hypertension were more frequently observed
in non-survivors than in survivors (all P<0.05). Among
pulmonary function test results, FEV1 (mean 1.32 L vs
1.41 L, P=0.044), FVC (mean 2.36 L vs 2.52 L, P=0.013),
and FVC % predicted (67.1% vs 70.8%, P=0.017) were
significantly lower in non-survivors than in survivors. The
FIB-4 was significantly higher in non-survivors than in
survivors (mean 1.8 vs 1.4, P<0.001).
Multivariate Cox Hazard Analysis for
All-Cause Mortality
Multivariate Cox hazard analysis to identify the indepen-
dent predictors of all-cause mortality is shown in Table 3.
Older age (HR=1.05, 95% CI 1.03–1.07), underlying
Figure 1 Flow chart for the selection of the study population. A total of 1282 patients with suspected COPD were considered eligible. Of these, 453 patients without PFT
results, history of asthma, and not COPD were excluded. Then, 73 patients with known chronic liver diseases were further excluded. Finally, 756 patients with COPD were
selected for the statistical analysis.
Abbreviations: COPD, chronic obstructive pulmonary disease; PFT, pulmonary function test.
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malignancy (HR=2.94, 95% CI 2.15–4.02), CAOD
(HR=1.58, 95% CI 1.10–2.26), higher GOLD stage
(HR=1.26, 95% CI 1.02–1.56), and higher FIB-4
(HR=1.15, 95% CI 1.03–1.27) were significantly asso-
ciated with the increased risk of all-cause mortality (all
P<0.05), whereas higher body mass index (HR=0.95, 95%




Age, years 67.9 ± 8.9
Sex, male 643 (85.1)
Body mass index, kg/m2 22.5 ± 3.2
Comorbidities
Malignancy 152 (20.1)
Cerebral vascular disease 67 (8.9)
Coronary artery occlusive disease 113 (14.9)
Congestive heart failure 93 (12.3)
Chronic kidney disease 54 (7.1)
Diabetes mellitus 131 (17.3)
Hypertension 254 (33.6)
Bronchiectasis 69 (9.1)
Destroyed lung 47 (6.2)
Smoking (n=731)
Ever smoker 603 (82.5)
Never smoker 128 (17.5)
Pulmonary Function Test Variables
FEV1, L 1.39 ± 0.52
FEV1, % predicted 57.0 ± 18.9
FVC, L 2.48 ± 0.79
FVC, % predicted 69.9 ± 18.6
FEV1/FVC, % 56.1 ± 10.1
Laboratory Variables
Hemoglobin, g/dL 13.7 ± 1.7
Platelet count, ×1000/μL 270.2 ± 93.8
Erythrocyte sedimentation, mm/hr 41.0 ± 36.1
C-reactive protein, mg/L 23.8 ± 48.5
Serum albumin, g/dL 4.2 ± 0.5
Blood urea nitrogen, mg/dL 16.5 ± 7.9
Serum creatinine, mg/dL 1.05 ± 0.33
Aspartate aminotransferase, IU/L 24.9 ± 23.3
Alanine aminotransferase, IU/L 23.2 ± 21.5
Total bilirubin, mg/dL 0.7 ± 1.1
FIB-4 1.53 ± 1.20
Note: Values are expressed as mean ± standard deviation or number (%).
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; FIB-4, fibrosis-4 index.











Age, years 66.9 ± 9.1 71.3 ± 7.9 <0.001
Sex, male 484 (83.2) 159 (91.4) 0.007
Body mass
index, kg/m2
22.6 ± 3.2 22.4 ± 3.4 0.554
Comorbidities
Malignancy 84 (14.4) 68 (39.1) <0.001
Cerebral vascular
disease
42 (7.2) 25 (14.4) 0.006
Coronary artery
occlusive disease
9 (11.9) 44 (25.3) <0.001
Congestive heart
failure
58 (10.0) 35 (20.1) 0.001
Previous
tuberculosis
131 (22.5) 44 (25.3) 0.474
Chronic kidney
disease
33 (57) 21 (12.1) 0.007
Diabetes mellitus 89 (15.3) 42 (24.1) 0.009
Hypertension 179 (30.8) 75 (43.1) 0.003
Bronchiectasis 58 (10.0) 11 (6.3) 0.177












FEV1, L 1.41 ± 0.53 1.32 ± 0.46 0.044
FEV1, % predicted 57.4 ± 19.3 55.7 ± 17.8 0.281
FVC, L 2.52 ± 0.81 2.36 ± 0.73 0.013
FVC, % predicted 70.8 ± 18.9 67.1 ± 17.4 0.017
FEV1/FVC, % 56.2 ± 10.4 55.7 ± 9.4 0.526
Laboratory Variables
Hemoglobin, g/dL 13.8 ± 1.7 13.4 ± 1.8 0.066
Platelet count,
×1000/μL
268.8 ± 90.3 273.7 ± 106.1 0.558
Eosinophil,/μL 251 ± 267 225 ± 229 0.283
Eosinophil, % 3.2 ± 2.9 2.9 ± 2.8 0.329
Erythrocyte
sedimentation, mm/hr
37.2 ± 32.9 51.6 ± 42.5 0.057
C-reactive
protein, mg/L
21.0 ± 47.3 28.9 ± 50.4 0.124
(Continued)
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CI 0.89–0.99) was independently protective for all-cause
mortality (all P<0.05).
The study population was stratified into three risk
groups (low [Q1], intermediate [Q2-3], and high [Q4]
FIB-4 groups). The high FIB-4 group (>1.57) had
a significantly lower cumulative survival rate than the
low FIB-4 group (≤1.05) (P=0.031, Log-rank test)
(Figure 2).
Multivariate Regression Analysis for the
Relationship Between FIB-4 and Acute
Exacerbation
The number of patients who had ever experienced acute
exacerbation during the follow-up duration was 468
(61.9%), and the mean number of acute exacerbations of
COPD per year was 0.42 in this study. On multivariate
regression analyses (Table 4), higher GOLD stage
(OR=1.19, 95% CI 1.07–1.34) was independently asso-
ciated with the increased risk of acute exacerbation,
whereas higher FIB-4 (HR=1.05, 95% CI 1.01–1.15) was
independently associated with the increased risk of acute
exacerbation (all P<0.05).
Discussion
Based on the hypothesis that liver fibrosis, a sequela of
hepatic or systemic inflammation, may act as an unfavorable
prognostic factor in patients with COPD, we investigated the
relationship between fibrotic burden in liver and COPD.
Towards this, we used FIB-4 and various clinical outcomes,
including all-cause mortality and acute exacerbations in
patients with COPD. Finally, we found that higher FIB-4
independently predicted the higher risk of all-cause mortality
and acute exacerbations. In addition, the higher FIB-4 group
showed a significantly lower cumulative survival than the
low FIB-4 group. The cutoff of FIB-4 to defined higher FIB-
4 group in this study was 1.57, which is quite similar to the
established cutoff of 1.45 indicating the presence of signifi-
cant liver fibrosis (≥ stage 2 fibrosis).8
COPD is a complex respiratory disease with systemic
inflammation frequently accompanying various comorbid-
ities such as cardiovascular disease, lung cancer, metabolic
syndrome, depression, and dysfunctional skeletal
myopathy.18,19 All these comorbidities impact on prog-
nosis, quality of life, and physical activities of patients
with COPD, and play a major role in the classification of
the various phenotypes of COPD. Interest regarding liver
diseases in patients with COPD has been increasing
recently. NAFLD is highly prevalent and is considered as
one of the contributors of cardio-metabolic comorbidities










Serum albumin, g/dL 4.3 ± 0.5 4.1 ± 0.6 0.006
Blood urea
nitrogen, mg/dL
15.9 ± 6.8 18.1 ± 10.3 0.054
Serum
creatinine, mg/dL








22.8 ± 16.2 24.8 ± 33.5 0.452
Total bilirubin, mg/dL 0.6 ± 0.3 0.9 ± 2.1 0.219
FIB-4 1.4 ± 0.8 1.8 ± 2.0 <0.001
Note: Values are expressed as mean ± standard deviation or number (%).
Abbreviations: FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity;
FIB-4, fibrosis-4 index.
Table 3 Multivariate Cox Hazard Model to Identify Independent





Age, years 1.05 1.03–1.07 <0.001
Sex, male 1.67 0.94–2.94 0.080
Body mass index, kg/m2 0.95 0.89–0.99 0.031
Comorbidities
Malignancy 2.94 2.15–4.02 <0.001




Chronic kidney disease 1.38 0.84–2.25 0.205
Diabetes mellitus 1.29 0.88–1.88 0.187
Hypertension 1.10 0.78–1.56 0.570
Pulmonary Function Test
Variables
GOLD stage, as one stage
increases
1.26 1.02–1.56 0.036
FIB-4 1.15 1.03–1.27 0.010
Abbreviations: CI, confidence interval; FIB-4, fibrosis-4 index; GOLD, global
initiative for chronic obstructive lung disease.
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analysis, NAFLD is strongly associated with reduced pul-
monary function. Reduced lung volumes at baseline were
also associated with increased NAFLD incidence, espe-
cially in Asians.6 However, only a few studies have inves-
tigated how fibrotic burden in the liver impacts the
outcomes of patients with COPD.18,21
Divo et al investigated various comorbidities and their
influence on the risk of mortality in patients with COPD.18
Although the prevalence of liver cirrhosis was lower than
that of cardiovascular and metabolic diseases, liver cirrho-
sis was significantly associated with the increased risk for
death.18 Contrarily, our current study recruited only
patients with a milder fibrotic burden in the liver after
excluding those with known liver disease. Nevertheless,
subtle or subclinical fibrosis progression in the liver,
reflected by a higher FIB-4, was independently associated
with a higher risk of mortality and acute exacerbation.
This might mean that fibrotic burden in the liver might
have a prognostic implication in patients with COPD.
Indeed, in a recent longitudinal study, it was evident that
liver fibrosis, not just liver steatosis, was independently
associated with long-term overall mortality in patients
with NAFLD.22 This issue is further supported by
Viglino et al who reported a three-fold higher risk of
developing the first cardiovascular event and death in
patients with COPD with co-existing liver fibrosis—
assessed using another non-invasive patented surrogate,
FibroTest®—when compared to those without liver
fibrosis.21,23
Several comorbidities are associated with increased
risk of acute exacerbation in patients with COPD, such
Figure 2 The cumulative survival rate according to FIB-4. When the study population was stratified into three risk groups (low [Q1], intermediate [Q2-3], and high [Q4]
FIB-4 groups), the high FIB-4 (>1.57) group had a significantly lower cumulative survival rate than the low FIB-4 (≤1.05) group (P=0.031, Log-rank test).
Abbreviation: FIB-4, fibrosis-4 index.
Table 4 Multivariate Regression Analysis for the Relationship




Age, years 0.99 0.98–1.01 0.277
Sex, male 1.21 0.93–1.59 0.155
Body mass index, kg/m2 1.01 0.99–1.03 0.501
GOLD stage, as one stage
increases
1.19 1.07–1.34 0.002
FIB-4 1.08 1.01–1.15 0.034
Abbreviations: CI, confidence interval; FIB-4, fibrosis-4 index; GOLD, global
initiative for chronic obstructive lung disease.
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as gastro-esophageal reflux disease, anxiety, depression,
pulmonary embolism, pulmonary hypertension, and cardi-
ovascular disease.1 In addition to previously known
comorbidities, higher FIB-4 was independently associated
with the increased risk of acute exacerbation in our current
study. In contrast, liver disease did not impact the rate of
acute exacerbations in the study by Viglino et al, with only
a severe level of exacerbation noted in emergency admis-
sion, hospitalization, and the intensive care unit.21 The
authors demonstrated a tendency of an increase in the
risk of acute exacerbation-related hospitalization in those
with liver fibrosis (P=0.06). We included both moderate
and severe exacerbation cases; however, increased FIB-4
was not associated with each type of exacerbation (data
not shown). Moreover, airflow limitation was less severe
among the participants of the study by Viglino et al, result-
ing in a lower proportion of patients who had experienced
at least one exacerbation in contrast to that in our study
(45.9% vs 61.9%).
There are several common pathophysiologic mechan-
isms shared between COPD and liver fibrosis. First, COPD
and liver fibrosis are characterized by similar inflamma-
tory processes involving tumor necrosis factor-alpha,
transforming growth factor-beta, leptin, and
adiponectin.24–29 These pro-inflammatory mediators pro-
mote tissue damage and remodeling in the lung and con-
tribute to the progression of liver fibrosis. In addition,
chronic intermittent hypoxia induces liver fibrosis through
several pathways. In the study on rodent models of sleep
apnea, Toll-like receptor 4-mediated mitogen-activated
protein kinase and nuclear factor-kB signaling were related
to increased liver fibrosis.30 Moreover, hepatocyte
hypoxia-inducible factor-1 induced liver fibrosis in
a mouse model of NAFLD due to liver tissue hypoxia in
hepatic steatosis.31 Thirdly, the process of aging has been
considered as a risk factor for the development and pro-
gression of COPD and liver fibrosis. Aging is generally
related with increased oxidative stress and reduced toler-
ance to oxidative damage.32 Moreover, immunosenescence
is unavoidable with increasing age, resulting in various
clinical consequences including increased susceptibility
to infection, malignancy, and autoimmunity.33,34
Increased inflammatory reaction mainly composed of
CD4+ lymphocytes and macrophages expressing TH2 cyto-
kines is the main factor involved in the higher suscept-
ibility to liver fibrosis with increasing age.35 Increased
CD4+ and CD8+ T cells in the airway and lung parench-
yma are also major COPD-related changes.36
This study has several limitations. Firstly, because of
the absence of a control group, we were not able to assess
the impact of liver fibrosis on the clinical outcomes in
COPD compared to that in a control group. In addition,
the degree of liver fibrosis was noninvasively assessed
using FIB-4 without detailed histological information.
However, the simple-to-use FIB-4 has been validated
and widely used to assess the degree of liver fibrosis
and cirrhosis in chronic liver disease.8–10 Thirdly,
NAFLD is a major liver disease that progresses to liver
fibrosis, and metabolic syndrome is an essential comor-
bidity that contributes to the progression of liver fibrosis.
Unfortunately, NAFLD and metabolic syndrome pre-
sence-related data were not available for this study.
Lastly, because of the unavailability of data on cause of
death, only all-cause mortality was assessed, and thus, the
effect of liver fibrosis on mortality from COPD was not
evaluated.
Conclusion
A higher fibrotic burden assessed using FIB-4 at the diag-
nosis of COPD was independently predictive of the
increased risk of all-cause mortality and acute exacerba-
tion in patients with COPD without chronic liver diseases.
FIB-4, a non-invasive, simple-to-use, and readily available
tool in daily clinical practice, could play a role as
a prognostic tool representing liver fibrosis in patients
with COPD.
Abbreviations
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